# Diabetes Research Hub — Monitor Review

**Run:** 2026-06-18 (automated, scheduled monitor)
**Compares:** snapshot 2026-06-17 → 2026-06-18
**Evidence standard:** Research Doctrine v1.0 — new claims labeled by validation level

---

## Headline (what's actionable today)

1. **FDA approval, June 12: Tzield (teplizumab) for pediatric Stage 3 T1D (ages 8–17).** [Certain — FDA press announcement] Most significant external event this week; it directly intersects our tracked therapies and trials. See Breaking News + Recommended Actions.
2. **7 new trials** ingested; **0 status changes, 0 new results posted.** Routine churn — only the new Phase 3 (UBT251) is worth a tracker entry.
3. **27 new / 25 dropped PubMed papers**, 8 cross-domain. The teplizumab + CGM and teplizumab + MS/T1D papers are timely given the approval.
4. **Gap analysis pair data is ~59 days stale; the curated "Notable Trials to Watch" table is still empty** — the single highest-leverage manual task outstanding.

---

## File System Status

| File | Last modified | State |
|------|--------------|-------|
| clinical_trials_latest.json | 2026-06-18 07:05 | Fresh |
| pubmed_recent_latest.json | 2026-06-18 07:05 | Fresh |
| hub_monitor_report.md | 2026-06-18 07:06 | Fresh |
| literature_gap_report.md | 2026-06-17 08:08 | 1 day old — OK |
| literature_gap_data.json | 2026-04-20 15:35 | **~59 days old — STALE** |
| literature_gap_matrix.xlsx | 2026-04-20 | **~59 days old — STALE** |

hub_monitor flagged **724 result files >14 days old**, but most are dated daily snapshots (intended archive) and large one-off analysis JSONs. The only stale file feeding an active workflow is the gap-analysis pair (`literature_gap_data.json` / matrix): the human-readable report was refreshed 06-17, but the underlying pair-count data dates to April 20. Worth a re-run.

The hub_monitor_report shows its hub root under a different session path (`/sessions/eloquent-beautiful-faraday/...`) than this run — expected, reflects whichever session generated the snapshot. No data impact.

---

## Clinical Trial Changes

**Snapshot diff (06-17 → 06-18):** +7 new, 0 removed, 0 status changes, 0 new results. Total tracked: **820 unique trials** (263 RECRUITING, 124 PHASE3).

**New trials (7):** Only one is high-priority:

- **NCT07653477 — UBT251 injection, Phase 3, T2D inadequately controlled on metformin** (sponsor: United Bio-Technology (Hengqin) Co.). Status NOT_YET_RECRUITING. UBT251 is a **GLP-1/GIP/glucagon triple agonist** — same class as retatrutide. New Phase 3 entrant in the incretin race. **Worth a tracker entry.** [Likely — based on title/class; confirm mechanism on ClinicalTrials.gov]

The other six are device/observational/completed and low-priority: NCT07655076 (early-phase device, ClinSurge), NCT05795582 (photoplethysmography, CHU Nice), NCT07652528 (CGM patch pump vs basal-bolus, Hallym — observational NA), NCT07532564 (ED boarding costs, completed), NCT05144802 (Dexcom/Libre accuracy under hypoxemia, completed), NCT03837405 (DELISH diet-education study, UCSF, completed).

**Key Phase 3 trials from priority sponsors currently RECRUITING** (unchanged this week, for situational awareness):

| NCT | Sponsor | Therapy / focus |
|-----|---------|-----------------|
| NCT06832410, NCT04786262 | Vertex | VX-880 / zimislecel (islet cell therapy, T1D) |
| NCT07222332, NCT07222137 | Eli Lilly | Baricitinib — beta-cell preservation / delay of Stage 3 T1D in children & adolescents |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly basal) |
| NCT07564414 | Novo Nordisk | CagriSema |
| NCT06739122 | Eli Lilly | Dulaglutide 3.0/4.5 mg, pediatric |

No recently-posted results to review this cycle.

---

## PubMed Highlights

170 unique papers across 16 alert domains (30-day lookback). Domain volumes are uniform (~10/domain) because the harvester caps per-domain pulls; LADA (8) and Drug Repurpose (4) under-filled, GLP-1 Pharmacogenomics (3) lowest — consistent with their small literature bases, not an ingestion fault.

**Cross-domain papers (highest value — 8 this cycle):**

- **[42269843]** Targeting shared immune pathways in MS and T1D — *T1D Immunotherapy × teplizumab*. Timely given the FDA pediatric approval.
- **[42267680]** Early assessment of teplizumab response using CGM — *T1D Immunotherapy × teplizumab*. Directly relevant to monitoring the newly-approved pediatric indication.
- **[42294227]** Liraglutide + dapagliflozin synergistically reshape gut microbiota & metabolic profiles — *Biomarker × Multi-Omics × dapagliflozin*. Combination-mechanism signal; relevant to Tier-1 drug-repurposing/combination work.
- **[42296503]** Living systematic review of pharmacologic obesity treatments — *orforglipron × retatrutide*.
- **[42198313]** Diabetes & stroke, GLP-1 therapeutic potential — *retatrutide × CagriSema*.
- **[42306490]** CGM-derived postprandial glucose, IcoSema vs other insulins — *T2D GLP-1 × icodec*.
- **[42307637]** PCOS integrated review — *T2D GLP-1 × Drug Repurpose*.
- **[42307079]** Metabolism/cognition pipeline, Down syndrome mouse model — *Biomarker × Microbiome*.

**Key-therapy tracker:** all 8 tracked therapies (zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, icodec, dapagliflozin) had hits this cycle. Teplizumab is the one to read closely this week.

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score, BRONZE — single-source, expert confirmation required):

1. **Beta Cell Regen × Health Equity** — 100.0, 0 joint pubs
2. **Insulin Resistance × Islet Transplant** — 100.0, 1 joint pub
3. **Islet Transplant × Drug Repurposing** — 100.0, 0 joint pubs
4. **Islet Transplant × Health Equity** — 100.0, 0 joint pubs
5. **Gene Therapy × LADA** — 100.0, 0 joint pubs

**Alignment with Tier-1 contribution areas (RESEARCH_DOCTRINE.md):**

- Gap #3 (Islet Transplant × Drug Repurposing) maps directly to **Tier-1 #4 Drug Repurposing Computational Screening** — and we already have an islet-repurposing pipeline (`islet_repurposing_*` outputs, April). Actionable with existing assets.
- Gaps #1 and #4 (Health Equity intersections) map to **Tier-1 #6 Epidemiological / Health-Equity Analysis**.
- Gap #5 (Gene Therapy × LADA) is a synthesis target, but check it isn't a terminology artifact before investing.

Caveat per doctrine: these are keyword-based BRONZE findings. Several "100.0 / 0 joint pubs" pairs likely reflect terminology mismatch, not true voids. Verify with combined-term PubMed searches before treating any as a real opportunity.

---

## Breaking News (web, last 7 days)

- **[Certain] FDA approved Tzield (teplizumab), June 12, 2026** — accelerated approval extending the indication to pediatric patients ages 8–17 recently diagnosed with Stage 3 T1D, to delay decline of insulin production. First approved treatment for this group. (FDA / Sanofi / Breakthrough T1D, June 12–13.) Significant for the hub: teplizumab is a tracked therapy, two cross-domain teplizumab papers landed this cycle, and Lilly's baricitinib Phase 3 trials target the same "delay Stage 3 T1D in children" goal — a competitive/complementary landscape now worth a dedicated synthesis note.
- **[Likely] ADA 2026 Scientific Sessions, New Orleans, June 5–8** (just outside the 7-day window). Notable reported readout: **Tegoprubart** — all 12 trial participants reportedly off external insulin. If accurate, a meaningful islet/immunomodulation signal; verify primary source before logging.
- No other FDA diabetes actions in the last 7 days beyond Tzield (earlier-2026 approvals: Awiqli/icodec Mar 26, generic dapagliflozin, Langlara biosimilar Apr 29 — already historical).

---

## Recommended Actions

1. **Log the teplizumab pediatric approval as a hub event** and write a short synthesis note tying it to (a) the two new teplizumab cross-domain papers [42269843, 42267680] and (b) Lilly's baricitinib Stage-3-delay Phase 3 trials (NCT07222332 / NCT07222137). The week's only genuinely new strategic development. [Tier-1 #3 Clinical Trial Intelligence]
2. **Add UBT251 (NCT07653477) to the "Notable Trials to Watch" table** in `clinical_trials_summary.md` — currently empty. Flag as triple-agonist Phase 3, T2D. Confirm mechanism on ClinicalTrials.gov first.
3. **Re-run gap analysis** — `literature_gap_data.json` / `literature_gap_matrix.xlsx` are ~59 days old (Apr 20). Run: `python project1_literature_gap_analysis.py`.
4. **Verify gap #3 (Islet Transplant × Drug Repurposing)** against the existing `islet_repurposing_*` outputs — this BRONZE gap aligns with a Tier-1 area and may already be partly addressed by your April pipeline. Promote to SILVER if covered.
5. **Verify the Tegoprubart ADA readout** from a primary source before treating "12/12 off insulin" as established. [Currently Guessing → needs primary source]
6. No tracker update needed for the 6 device/observational/completed new trials.

---

*Generated by the automated Diabetes Research Hub monitor. Review-only run — no existing files modified. All new external claims labeled by confidence; trial/therapy interpretations are BRONZE pending verification per Research Doctrine.*
